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Abstract
Introduction: Previous studies established that prion disease with unique strain-specific phenotypes could be
induced by in vitro-formed recombinant PrP (rPrP) fibrils with structures different from that of authentic prions, or
PrPSc. To explain the etiology of prion diseases, new mechanism proposed that in animals the transition from rPrP
fibrils to PrPSc consists of two main steps: the first involves fibril-induced formation of atypical PrPres, a self-replicating
but clinically silent state, and the second consists of atypical PrPres-dependent formation of PrPSc via rare deformed
templating events.
Results: In the current study, atypical PrPres with characteristics similar to those of brain-derived atypical PrPres was
generated in vitro. Upon inoculation into animals, in vitro-generated atypical PrPres gave rise to PrPSc and prion disease
with a phenotype similar to those induced by rPrP fibrils. Significant differences in the sialylation pattern between atypical
PrPres and PrPSc suggested that only a small sub-fraction of the PrPC that is acceptable as a substrate for PrPSc could be
also recruited by atypical PrPres. This can explain why atypical PrPres replicates slower than PrPSc and why PrPSc
outcompetes atypical PrPres.
Conclusions: This study illustrates that transmissible prion diseases with very similar disease phenotypes could be
produced via two alternative procedures: direct inoculation of recombinant PrP amyloid fibrils or in vitro-produced
atypical PrPres. Moreover, this work showed that preparations of atypical PrPres free of PrPSc can give rise to transmissible
diseases in wild type animals and that atypical PrPres generated in vitro is an adequate model for brain-derived atypical
PrPres.
Introduction
Prions are proteinaceous infectious agents that are
underlying causes of fatal neurodegenerative diseases
known as prion diseases or transmissible spongiform en-
cephalopathies (TSE) [1]. Prions consist of misfolded,
aggregated states of the normal, cellular form of the
prion protein (PrPC). Prion diseases can arise spontan-
eously, be inherited or be acquired through transmission
[1]. Prions spread between organisms or from cell to cell
by replicating their disease-specific misfolded structures
via a template-assisted mechanism [2]. This mechanism
postulates that PrPSc template recruits and converts
PrPC expressed by a host into PrPSc. According to this
mechanism, the folding pattern of a newly formed PrPSc
accurately replicates that of the PrPSc template, and
prion replication exhibits high fidelity [2].
Recent studies demonstrated that in the presence of
certain cellular components such as RNA and/or lipids,
highly pure recombinant PrP converts into authentic PrPSc
conformations in vitro that can effectively induce transmis-
sible prion diseases in animals [3–6]. At the same time,
transmissible prion disease could also be induced by re-
combinant PrP (rPrP) amyloid fibrils formed in vitro in the
absence of any co-factors although at low efficiency [7–12].
Bearing in mind that the structures of rPrP fibrils produced
in vitro were found to be fundamentally different from that
of PrPSc [13, 14], these studies raised the possibility that an
unexplored mechanism responsible for the etiology of
prion diseases exists [15, 16]. According to this mechan-
ism, referred to as deformed templating, a self-replicating
state with one folding pattern can seed structurally differ-
ent self-replicating states with alternative folding patterns
when exposed to a new replication environment [16]. The
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newly generated self-replicating states that fit well to the
new environment outcompete the original template. A new
replication environment might include, but is not limited
to, new biochemical or cellular conditions, a new substrate
with altered amino acid sequence or posttranslational mod-
ifications, or presence of prion inhibitors [17–22]. In direct
support of the deformed templating mechanism, molecular
imaging revealed that switching between alternative folding
patterns can occur within individual PrP amyloid fibrils
when amyloid seeds were exposed to heterologous sub-
strate in vitro [23]. In another illustration of the deformed
templating mechanism, novel, structurally altered self-
replicating PrPSc states that were absent in the original
seeding material emerged upon changes to the biochemical
environment, which involved a depletion of RNA from
protein cyclic amplification reactions and subsequent
addition of RNA to the reactions [17]. In addition, upon
change in pH, non-infectious fibrils of recombinant fungal
prion protein HET-s with a stacked β-sheet architecture
gave rise to the alternative, infectious state of HET fibrils
with a β-solenoid structure [24].
Previous studies proposed that evolution of authentic
PrPSc from rPrP fibrils consists of two main steps [11, 12]
(Fig. 1). The first step involves formation of atypical
PrPres, a self-replicating state that is triggered in animals
upon inoculation of rPrP fibrils. While atypical PrPres is
transmissible, it is clinically silent and not neurotoxic [25].
In a second step, atypical PrPres give rise to PrPSc in rare
deformed templating events that are believed to be sto-
chastic in nature. Because atypical PrPres and PrPSc are
significantly different in structure [11, 12, 26, 27], a transi-
tion from the former to the latter is believed to represent
the major barrier to the evolution of authentic PrPSc.
The current work is inspired by recent findings that
atypical PrPres with characteristics similar to those of
brain-derived atypical PrPres can be generated in vitro
by seeding Protein Misfolding Cyclic Amplification reac-
tions with beads (PMCAb) using rPrP fibrils (Fig. 1).
Three questions have been asked in the current work.
The first is whether atypical PrPres generated in vitro
gives a rise to PrPSc and prion disease in animals (Fig. 1).
The second is whether the strain-specific disease pheno-
type associated with in vitro-generated atypical PrPres is
similar to those of synthetic strains produced by direct
inoculation of animals by rPrP fibrils. The third is
whether evolution of authentic PrPSc and development
of prion diseases can be accelerated if the first of the
two main steps, i.e. formation of atypical PrPres, is
accomplished in vitro.
Materials and methods
Expression and purification of rPrP and formation of rPrP
fibrils
Syrian hamster full-length rPrP encompassing residues
23–231 was expressed and purified according to a previ-
ously described procedure [28] with minor modifications
[10]. Lyophilized rPrP was dissolved in 5 mM HEPES,
pH 7.0, immediately before use. To form fibrils, a mix-
ture of 0.5 mg/ml rPrP with 50 mM MES, pH 6.0, and
2.0 M or 0.5 M guanidine hydrochloride (GdnHCl) was
Fig. 1 Schematic illustration of two alternative pathways for generating PrPSc. The first pathway was established in previous studies [11, 12], it involves
direct inoculation of in vitro-generated rPrP fibrils into animals and consists of two main steps. In a first step, rPrP fibrils seeded atypical PrPres,
a transmissible form of PrP that replicates silently without causing clinical disease. In a second step, atypical PrPres produces PrPSc in rare and
stochastic seeding events that are described by a deformed templating mechanism [16]. PrPSc replicates faster than atypical PrPres and eventually
replaces it during serial passages. An alternative pathway is under investigation by the current work. In vitro-generated rPrP fibrils were used to seed
serial dgPMCAb that produced fibril-induced atypical PrPres, which was inoculated into animals
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incubated at 37 °C under continuous agitation. Amyloid
formation was confirmed by thioflavin T fluorescence assay
as described previously [28]. Fibrils were dialyzed against
10 mM sodium acetate, pH 5.0 for storage. If required,
fibrils were heat-treated in PBS, pH 7.4 in the presence of
5 mg/ml BSA (Sigma, Cat. #A3294) or 5 % brain homogen-
ate prepared from healthy hamsters (see below) as
described before [10, 29].
Preparation of 10 % brain homogenate (BH)
10 % (wt/vol) brain homogenates were prepared in
PBS, pH 7.4, using glass/Teflon homogenizers attached
to a cordless 12 V compact drill (Ryobi) as previously
described [30].
Protein misfolding cyclic amplification with beads
(PMCAb)
10 % normal brain homogenate (NBH) from healthy
hamsters was prepared as described previously [12] and
used as a substrate for PMCAb [31]. For the first round,
10 μl of water-diluted rPrP fibrils were added to 90 μl of
NBH resulting in the 5 μg/ml final rPrP concentration in
the reaction. For the reactions seeded with brain-derived
PrPSc, 10 μl of scrapie BH from inoculated animals were
diluted in PBS to achieve the desired final concentration
and added to 90 μl of NBH. The standard sonication
program consisted of 20 s sonication pulses at ~150 W
applied every 20 min during a 24 h period. For each sub-
sequent round, 10 μl of the reaction from the previous
round were added to 90 μl of fresh substrate. Each
PMCAb reaction was carried out in the presence of two
3/32” Teflon beads (amazonsupply.com). To analyze
production of PK-resistant PrP material in PMCAb,
10 μl of sample were supplemented with 5 μl of SDS
and 5 μl of PK to a final concentration of SDS and PK of
0.25 % and 50 μg/ml, respectively, followed by incuba-
tion at 37 °C for 1 h. The digestion was terminated by
addition of SDS-sample buffer and heating the samples
for 10 min in a boiling water bath.
Protein misfolding cyclic amplification with partially
deglycosylated substrate (dgPMCAb) and generation of
atypical PrPres in vitro
To produce substrate for dgPMCAb, 10 % NBH from
healthy hamsters prepared for PMCAb was treated with
peptide-N-glycosidase F (PNGase F) (New England
BioLabs, glycerol-free) as follows. After preclearance of
NBH at 500 × g for 2 min, 1500 U/ml PNGase F was
added to the supernatant, and the reaction was incu-
bated on a rotator at 37 °C for 5 h. The resulting sub-
strate was used in dgPMCAb with sonication conditions
described for PMCAb. To produce brain-derived atypical
PrPres, dgPMCA substrate was treated with RNase A
(Sigma, catalog no. R4875) for 1 h at 37 °C as described
previously [32], and seeded with 109-fold diluted brain
material of the animal from the second passage of syn-
thetic strain S05 [11], which contained predominantly
atypical PrPres. dgPMCAb was carried out for 18 rounds
with 10-fold dilution between rounds. The absence of
PrPSc in the final product was confirmed by failure to
amplify in 6 rounds of PMCAb (Fig. 2d).
Bioassay
Each hamster received 50 μl of inoculum intracerebrally,
under 2 % O2/4 minimum alveolar concentration (MAC)
isoflurane anesthesia. After inoculation, animals were ob-
served daily for disease using a ‘blind’ scoring protocol.
The study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The animal protocol was approved by the Institutional
Animal Care and Use Committee of the University of
Maryland, Baltimore (Assurance Number A32000-01;
Permit Number: 0215002).
Proteinase K digestion of brain homogenates
For the PK digestion in sarcosyl, an aliquot of 10 % BH
was prepared as described previously [30]. Briefly, 10 %
BH was mixed with an equal volume of 4 % sarcosyl in
PBS, supplemented with 50 mM Tris, pH 7.5, and
digested with 20 μg/ml PK (New England BioLabs) for
30 min at 37 °C with 1000 rpm shaking using a DELFIA
plate shaker (Wallac) placed in 37 °C incubator. PK
digestion was stopped by adding SDS sample buffer and
heating the samples for 10 min in a boiling water bath.
Samples were loaded onto NuPAGE 12 % Bis-Tris gels,
transferred to PVDF membrane, and probed with 3F4 or
SAF-84 antibodies.
Analysis of conformational stability and Proteinase K
resistance
10 % brain homogenate was diluted 10 times into PMCAb
conversion buffer, then supplemented with an equal vol-
ume of GdnHCl solution in PBS to a final concentration
of GdnHCl ranging from 0.4 to 4 M, and incubated at
room temperature for 1 h. Next, nine volumes of 2 %
sarkosyl in PBS were added to all samples followed by 1 h
incubation at room temperature, and then the samples
were treated with 20 μg/mL PK for 1 h at 37 °C with shak-
ing. The digestion was stopped with 2 mM PMSF, and
the proteins were precipitated in four volumes of ice-
cold acetone, incubated overnight at −20 °C, and subse-
quently centrifuged for 30 min at 16000 x g. Pellets
were dried for 30 min, resuspended in 1 × SDS-sample
buffer, loaded into NuPAGE 12 % bisTris gels, then
transferred to PVDF membrane, and stained with 3F4
or SAF-84 antibody. To analyze PK resistance, 10 % BH
was diluted 10-fold into PMCAb conversion buffer,
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then supplemented with 0.2 % SDS and digested with
serially diluted glycerol-free PK (Sigma, Cat. # P6556)
for 1 h at 37 °C. The digestion was terminated by
addition of SDS-sample buffer and heating the samples
for 10 min in a boiling water bath.
PNGase F treatment of PrPSc
10 % brain homogenate was diluted with an equal volume
of 4 % sarcosyl in PBS, pH 7.4, digested with 20 μg/ml PK
as described above, deglycosylated following the proced-
ure described previously [10], and assayed by Western blot
with 3 F4 antibody.
2D electrophoresis
25 μL samples were heated for 10 min in a boiling water
bath in the presence of gel loading buffer, solubilized for
1 h at room temperature with 200 μL solubilization buffer
(8 M Urea, 2 % (wt/vol) CHAPS, 5 mM TBP, 20 mM
TrisHCl pH 8.0), then alkylated by adding 7 μL of 0.5 M
iodoacetamide and incubated for 1 h at room temperature
in the dark. Then, 1150 μL of ice-cold methanol was
added and samples were incubated for 2 h at −20 °C. After
centrifugation at 16,000 g at 4 °C, supernatant was
discarded and the pellet was re-solubilized in 160 μL
rehydration buffer (7 M urea, 2 M thiourea, 1 % (wt/vol)
DTT, 1 % (wt/vol) CHAPS, 1 % (wt/vol) Triton X-100,
1 % (vol/vol) ampholyte, trace amount of Bromophenol
Blue). Fixed immobilized pre-cast IPG strips (cat. #
ZM0011, Life Technologies, Carlsbad, CA) with a linear
pH gradient 3–10 were rehydrated in 155 μL of result-
ing mixture overnight at room temperature inside IPG
Runner cassettes (cat. # ZM0008, Life Technologies).
Isoelectrofocusing (first dimension separation) was per-
formed at room temperature with rising voltage (175 V
for 15 min, then 175–2,000 V linear gradient for
45 min, then 2,000 V for 30 min) on Life Technologies
Zoom Dual Power Supply using the XCell SureLock
Mini-Cell Electrophoresis System (cat. # EI0001, Life
Technologies). The IPG strips were then equilibrated
for 15 min consecutively in (i) 6 M Urea, 20 % (vol/vol)
glycerol, 2 % SDS, 375 mM Tris-HCl pH 8.8, 130 mM
DTT, and (ii) 6 M Urea, 20 % (vol/vol) glycerol, 2 %
SDS, 375 mM Tris-HCl pH 8.8, 135 mM iodoacetamide,
and loaded on 4–12 % Bis-Tris ZOOM SDS-PAGE pre-
cast gels (cat. # NP0330BOX, Life Technologies). For
the second dimension, SDS-PAGE was performed for
1 h at 170 V. Immunoblotting was performed as
described elsewhere, blots were stained using 3F4 or
SAF-84 antibody.
Histopathological study
The brains of two animals from the second passage of F0.5-
derived atypical PrPres were evaluated for the presence of
spongiform changes and intensity of PrP immunostaining.
Formalin-fixed brain halves divided at the midline (left
hemisphere) were processed for hematoxylin-eosin (H&E)
stain and immunohistochemistry staining using the mouse
monoclonal anti-PrP antibody 3F4 (1:1000, Covance).
Blocks were treated in formic acid (96 %) before being em-
bedded in paraffin. For detection of disease-associated PrP,
Fig. 2 Generating rPrP fibril-induced atypical PrPres in dgPMCAb.
a Analysis of PK-resistant materials produced in 6th round of serial
PMCAb or dgPMCAb reactions seeded with four preparations of rPrP
fibrils or non-seeded reactions by Western blot. F2M or F0.5 are fibrils
generated in 2 M or 0.5 M GdnHCl, respectively, as previously described
[11]. FBSA or FNBH are fibrils annealed in BSA or NBH as previously
described [10, 29]. b Analysis of PK-resistant materials produced in
6th round of serial dgPMCAb reactions seeded with four independent
preparations of F0.5 fibrils or non-seeded reactions by Western blot.
c Establishing a limiting dilution for atypical PrPres in S05 brain material.
S05 brain material was subjected to 10-fold serial dilutions for up to
1013-fold and used for seeding serial dgPMCAb, using a procedure
previously described [34]. Western blot analysis of 18th serial dgPMCA
rounds demonstrates that 109-fold diluted S05 brain material was the
last dilution that contained atypical PrPres material. d To confirm that
preparation of brain-derived atypical PrPres subjected to 18th dgPMCA
rounds lacks PrPSc, serial PMCAb reactions were seeded with the
products of 18th dgPMCAb round or 109-fold diluted S05 brain
material, then subjected to six serial PMCAb rounds and analyzed
by Western blot. PK-resistant bands at 23, 16 and 13 kDa represent
di-, mono- and unglycosylated atypical PrPres, respectively. Western
blots in panels a-c were stained with SAF-84 antibody and in panel
d with 3F4 antibody
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blocks were pretreated by 15 min hydrated autoclaving at
121 °C in trisodium citrate buffer, pH 6.0 with 0.05 %
Tween 20, followed by 5 min in 88 % formic acid.
Results
Triggering atypical PrPres in vitro is a generic property of
rPrP fibrils
In previous studies, upon inoculations into animals, rPrP
fibrils were shown to induce misfolding of PrPC into atyp-
ical PrPres [11, 12]. To test whether this process could be
recapitulated in vitro, rPrP fibrils were prepared according
to the protocols used in previous studies for making fibrils
that induced transmissible prion diseases [10–12, 29].
Regardless of the experimental protocol, all fibril prepara-
tions triggered atypical PrPres in a PMCAb format that
used partially deglycosylated PrPC substrate, referred to as
dgPMCAb (Fig. 2a) [26]. Notably, dgPMCAb was previ-
ously found to favor selective replication of brain-derived
atypical PrPres over PrPSc [26]. When serial PMCAb reac-
tions, instead of dgPMCAb, were seeded with the same
fibril preparations, no PK-resistant products were found
(Fig. 2a). This result is in agreement with the previous
studies that rPrP fibrils do not seed PrPSc nor contain small
amounts of PrPSc amplifiable by PMCAb [11, 12, 33]. rPrP
fibril-induced formation of atypical PrPres in dgPMCAb
was robust and highly reproducible (Fig. 1b). No PK-
resistant products were found in non-seeded dgPMCAb
control reactions (Fig. 1b). For further experiments, we
choose rPrP fibrils prepared in 0.5 M GdnHCl (abbreviated
as F0.5), as they were the most effective in inducing prion
disease in animals [11].
In vitro preparation of atypical PrPres materials for animal
bioassay
To prepare atypical PrPres for inoculation, dgPMCAb reac-
tions were seeded with F0.5 fibrils and subjected to ten
serial rounds. The products of the 10th rounds, abbreviated
as F0.5-induced atypical PrPres, were inoculated into Syrian
hamsters. In parallel to the F0.5-induced atypical PrPres,
brain-derived atypical PrPres material free of PrPSc was also
produced for inoculation using the following strategy.
When subjected to a serial dgPMCAb, atypical PrPres
readily amplifies, whereas PrPSc does not. To ensure the
absence of PrPSc the following procedures were followed.
First, S05 brain material of an asymptomatic animal con-
taining predominantly atypical PrPres was used to seed
dgPMCAb [11]. Second, for seeding, this material was di-
luted 109-fold that corresponds to the limiting dilution of
atypical PrPres (Fig. 1c) (dgPMCAb titration of atypical
PrPres material is in Additional file 1: Figure S1). Third, the
substrate for dgPMCAb was treated with RNase, a proced-
ure that selectively amplifies atypical PrPres but not PrPSc
[26]. Fourth, 18 serial dgPMCAb rounds with 10-fold dilu-
tions between rounds were conducted to completely dilute
out any initial PrPSc material, if such would still present
after the initial 109-fold dilution (Fig. 2c). Moreover, to con-
firm absence of PrPSc in the preparation of brain-derived
atypical PrPres amplified in dgPMCAb, the products of the
18th dgPMCAb round were subjected to six serial PMCAb
rounds (Fig. 2d). Previously, we showed that six PMCAb
rounds were sufficient for amplifying a single PrPSc particle
to the amounts detectible by Western blot [34]. As
expected, no PrPSc was detected by Western blot after six
PMCAb rounds in the preparation of atypical PrPres
(Fig. 2d).
F0.5-induced atypical PrPres propagates in vivo and gives
rise to PrPSc
F0.5-induced atypical PrPres as well as S05 brain-derived
atypical PrPres amplified in dgPMCAb were inoculated
into two groups of wild type animals to test whether
atypical PrPres is able to give rise to PrPSc (Table 1,
Fig. 2). The results of these inoculations were compared
to the direct inoculation of F0.5 fibrils (Table 1). In
addition, S05 brain material, used to seed dgPMCAb for
production of brain-derived atypical PrPres, was also in-
oculated after dilution to 0.3 % to match the amount of
atypical PrPres, after 18 rounds of dgPMCAb (Table 1).
Two out of ten animals inoculated with F0.5-induced
atypical PrPres were sacrificed at 441 days post inocula-
tion. Atypical PrPres was found in their brains, proving
that fibril-derived atypical PrPres generated in vitro is
able to propagate in vivo (Fig. 3a). Because PK-resistant
bands of atypical PrPres and PrPSc overlap (Fig. 3b),
discrimination between the two forms required staining
Table 1 Bioassay of rPrP amyloid fibrils
Inoculum ns/nt
a nPKres/nt
b Euthanized, days post inocul.
F0.5 rPrP fibrils (1st passage) 0/7 6/7 723
F0.5 fibril-induced atypical PrPres (1st passage) 1/10 10/10 2 at 441, 582, 2 at 630, 5 at 636
Brain-derived atypical PrPres amplified in dgPMCA 0/4 4/4 606
atypical PrPres from S05 brainc 0/4 4/4 606
BH from animal inoculated with F0.5 fibril-induced atypical PrPres (2nd passage) 4/6 6/6 630
a number of animals with clinical signs over the total number of animals survived to the end of the experiment
b number of animals with PK-resistant PrP in BHs detectible by Western blot over the total number of animals survived to the end of the experiment
c 0.3 % brain material from the second passage of SO5 [11]
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with 3F4 (detects only PrPSc) and SAF-84 (stains both
PrPSc and atypical PrPres). While no PrPSc was found by
Western blot at 441 days post inoculation (Fig. 3a),
serial PMCAb revealed that small amounts of PrPSc
were present in brains of these animals (Fig. 3c). Later on,
at 476 days postinoculation, one out of eight animals
remaining in this group developed clinical signs similar to
those previously observed for synthetic hamster strains.
The disease progressed very slowly just like the slow pro-
gression in hamsters inoculated with other synthetic
strains [11, 12, 30]. This animal was euthanized 582 days
postinoculation. In addition to atypical PrPres, PrPSc was
detected by Western blot in the brain of the symptomatic
animal (Fig. 3a). The remaining, asymptomatic animals
were euthanized between 606 and 636 days postinocula-
tion (Table 1). None of the animals from the other groups
showed clinical disease, albeit atypical PrPres and PrPSc
were found in animals of all groups. In summary, animal
bioassay proved that atypical PrPres generated in vitro by
seeding dgPMCAb with rPrP fibrils replicated in vivo and
gave rise to PrPSc.
Transition from atypical PrPres to PrPSc and a competition
between atypical PrPres and PrPSc
To elucidate relationship between atypical PrPres and
PrPSc, the relative amounts of two states were compared
Fig. 3 Analysis of brain materials from the first passage. a Western blots of brain materials from animals inoculated with F0.5-induced atypical
PrPres and sacrificed at 441 days post-inoculation. Brain material from animal inoculated directly with F0.5 is included as a reference. b Schematic
representation of the PK resistance profile showing overlap between atypical PrPres and PrPSc, where atypical PrPres and PrPSc are represented by
gray and black boxes, respectively. c Western blot analysis of PK-resistant materials amplified in serial PMCAb reactions seeded with brain materials
from animals inoculated with F0.5-induced atypical PrPres and sacrificed at 441 days. d Western blots of brain materials from animals inoculated
with F0.5 fibrils, F0.5 fibril-induced atypical PrPres, 0.3 % S05 brain material or brain-derived atypical PrPres prepared as described in Fig. 2c. Western
blots were stained with SAF-84 or 3F4 antibody as indicated
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by Western blot in four groups: animals inoculated with
F0.5 fibrils, F0.5-induced atypical PrPres, S05 brain-derived
atypical PrPres amplified in dgPMCAb, and with diluted
S05 brain material not subjected to dgPMCA (Fig. 3b, d).
Several observations could be made. First, atypical PrPres
were found in all animals from all four groups, whereas
PrPSc were observed only in a fraction of animals and in
smaller amounts than atypical PrPres (Fig. 3d). Such
dynamics support the hypothesis that atypical PrPres is
the first product of PrPC misfolding, that it faithfully
propagates in vivo independently of PrPSc and that it
precedes PrPSc. Second, small amounts of PrPSc detecti-
ble by Western blot were found in the brains of animals
infected with the preparations of brain-derived atypical
PrPres amplified in dgPMCAb that lacked PrPSc. This
result suggests that atypical PrPres not only precedes,
but also gives rise to PrPSc. Not surprisingly, the highest
amounts of PrPSc were found in the group inoculated
with S05 brain material, since in addition to atypical
PrPres it contained small amount of PrPSc. Brain-
derived atypical PrPres enriched through dgPMCA
lacked PrPSc and thus resulted in formation of very low
amounts of PrPSc upon inoculation, similar to the amount
of PrPSc found in the brains inoculated with F0.5-induced
atypical PrPres. Interestingly, without the interference of
PrPSc, atypical PrPres accumulated to a greater degree.
Unexpectedly, PrPSc amounts accumulated in the brains of
animals inoculated with F0.5 fibril-induced or brain-derived
atypical PrPres did not exceed the amount of PrPSc found
in some animals inoculated with F0.5 fibrils. This observa-
tion, however, is consistent with the two-step mechanism,
according to which (i) atypical PrPres gives rise to PrPSc in
a stochastic manner and (ii) PrPSc competes with atypical
PrPres (Fig. 1). As judged from PK-resistance and con-
formational stability assays, both PrPSc and atypical PrPres
were extremely resistant to PK degradation and GdnHCl-
induced denaturation (Additional file 2: Figure S2). Such
high conformational stability and stability to proteolytic
degradation explains why both states can co-exist and
compete with each other for a long time. Upon inoculation
of high amounts of preformed atypical PrPres, PrPSc arises,
but has a low chance of outcompeting atypical PrPres in
the 1st passage.
Atypical PrPres and PrPSc are structurally different
Previous work established that atypical PrPres and PrPSc
have different structures, based on different the length
of the PK-resistant core, glycoform ratios and different
RNA-dependency for amplification [11, 12, 26, 27]. The
predominantly monoglycosylated composition of atypical
PrPres suggests that the diglycosylated glycoforms are
excluded from atypical PrPres, presumably due to strong
structural constraints and electrostatic repulsion be-
tween negatively charged terminal sialic acid residues on
N-linked glycans. Assuming that structural constraints
are much stronger in atypical PrPres than PrPSc, we
propose that diglycosylated, hypersialylated molecules
should be selectively excluded in atypical PrPres. To test
this hypothesis, distribution of charge isoforms that
reflects sialylation patterns of individual PrP molecules
within PrPSc or atypical PrPres were analyzed using 2D
(Fig. 4) [35]. In both states, unglycosylated molecules
showed more than one charge isoforms (Fig. 4). This
charge heterogeneity is largely attributed to the struc-
tural heterogeneity of the GPI anchors [36]. As expected,
in PrPSc the distribution of monoglycosylated isoforms
extended into acidic pH far beyond that of unglycosy-
lated isoforms, and the distribution of diglycosylated
isoforms extended into acidic pH beyond monoglycosy-
lated isoforms (Fig 4a). This is because diglycosylated
isoforms can incorporate more sialic acid residues per
molecule than monoglycosylated isoforms. In atypical
PrPres, the distribution of monoglycosylated isoforms
also extended into acidic pH far beyond that of ungly-
cosylated isoforms (Fig. 4b). However, diglycosylated
Fig. 4 2D analysis of sialylation status of PrPSc and atypical PrPres.
2D analysis of charge distribution of S05 brain-derived PrPSc (a) and
atypical PrPres from animals inoculated with F0.5 fibrils (b, upper panel),
atypical PrPres induced in animals by inoculating brain-derived atypical
PrPres amplified in dgPMCAb (b, middle panel), or asymptomatic S05
animals that lacked PrPSc (b, lower panel). Black triangles, white triangles
and arrows mark di-, mono-, and unglycosylated glycoforms,
respectively. The distributions of all three glycoforms of atypical
PrPres are shifted toward acidic pH relative to those of PrPSc due to
differences in number of charged amino acid residues and, accordingly,
pIs between atypical PrPres and PrPSc. All samples were treated with
PK. Western blots were stained with 3F4 (a) and SAF-84 (b)
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isoforms did not extend beyond monoglycosylated iso-
forms, illustrating that atypical PrPres excluded diglyco-
sylated molecules with high sialylation levels. Atypical
PrPres of three different origins were compared by 2D:
one induced in animals by inoculating F0.5 fibrils, atyp-
ical PrPres induced by inoculating brain-derived atypical
PrPres amplified in dgPMCAb, and atypical PrPres from
asymptomatic S05 animals [11]. They all showed very
similar if not identical sialylation patterns characterized
by the absence of hypersialylated diglycosylated mole-
cules, a pattern that was notably different from that of
PrPSc (Fig. 4).
Two alternative biochemical pathways produce synthetic
strains with similar disease phenotype
Next, we tested whether in vitro-generated atypical
PrPres results in a disease phenotype similar to those
previously described for the synthetic strains triggered
by inoculation of rPrP fibrils directly. Brain material
from the animal inoculated with F0.5-induced atypical
PrPres and euthanized at 441 days post inoculation was
used for the second passage. Using animal euthanized at
the early time point allowed initiating the second
passage approximately 200 days before the remaining
animals from this group were euthanized. In the second
passage, clinical disease was observed in 4 out of 6
animals after 500 dpi (Table 1). In agreement with the
slow disease progression of synthetic hamster strains
described previously [11, 12], the clinical disease here
progressed very slowly. Animals approached terminal
stages approximately 120 days after the first clinical
signs and were euthanized at 630 days due to the old
age. Animals displayed the same set of clinical symptoms
including rough coat, dry skin and obesity as was previ-
ously observed for the synthetic strains [10–12].
Consistent with TSE, histopathological analysis of ani-
mals from the second passage revealed a high degree of
spongiform vacuolation in multiple brain areas including
cerebellum, cortex, caudoputamen and thalamus (Fig. 5).
Diffuse, synaptic PrP immunoreactivity was observed in
the aforementioned subregions (Fig. 5). Large PrPSc pla-
ques were observed in the periventricular subependymal
region (Fig. 6), which is a hallmark of hamster synthetic
strains including S05 [11]. Perineuronal PrP deposits
were found in the thalamus, basal ganglia, and deeper
layers of the cortex (Fig. 6). Overall, the type and brain
regions of PrP depositions were consistent with deposi-
tions observed in the second passage of S05 strain pro-
duced upon direct inoculation of F0.5 fibrils [11].
Analysis of brain material from the 2nd passage of
F0.5-induced atypical PrPres revealed increased accumula-
tion of PrPSc, in addition to propagation of atypical PrPres
Fig. 5 Histopathological analysis. Spongioform changes stained with hematoxylin and eosine (upper panels) or PrP deposisiton stained with 3F4
antibody (lower panels) in hippocampus, thalamus, cerebellum, frontal cortex or caudoputamen in animals from the second passage of F0.5-induced
atypical PrPres that developed clinical disease. Scale bars = 200 μm
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(Fig. 7a). The dynamics between atypical PrPres and PrPSc
were very similar to those observed during serial passaging
of S05 strain that was produced upon inoculation of F0.5
fibrils directly. In the second passage of F0.5 the amounts of
PrPSc increased while atypical PrPres was still able to repli-
cate (Fig. 7b). For S05, the amounts of PrPSc formed in the
course of the second passage were variable and depended
on the ratio of PrPSc to atypical in the inoculums (Fig. 7b).
The dynamics between the two forms is consistent with the
hypothesis that the two forms compete with each other and
that PrPSc replaces atypical PrPres over time.
PNGase treatment revealed that the sizes of the PK-
resistant cores were the same for PrPSc from the second
passages of F0.5-induced atypical PrPres and the second
passage of S05, both of which were ~0.5-1 kDa shorter
than that of the 263K strain (Fig. 7c). In summary, the dis-
ease phenotype observed in a second passage of F0.5-in-
duced atypical PrPres was very similar, if not identical to,
that described in previous studies for S05 [11].
Discussion
The results in the current study are important for the
following reasons. First, this work illustrates that trans-
missible prion disease with very similar if not identical
disease phenotypes can be generated via two experi-
mental procedures that utilize alternative biochemical
pathways. The initial step of both pathways involves an
in vitro conversion of rPrP into an amyloid fibrilar state.
However, the first procedure involves direct inoculation
of rPrP fibrils into animals, whereas the second protocol
relies on production of atypical PrPres in vitro in reac-
tions seeded with rPrP fibrils. Second, this study pro-
vides the first direct illustration that preparations of
atypical PrPres free of PrPSc produced transmissible dis-
eases when inoculated into wild type animals. Atypical
PrPres is a self-replicating, transmissible, but clinically
silent state. Third, the current work provides strong sup-
port for the mechanism established in previous studies
and presented in Fig. 1 that atypical PrPres is an alterna-
tive transmissible state, which is also a precursor of
PrPSc [11, 12]. Fourth, the current study demonstrates
that atypical PrPres generated in vitro using dgPMCAb
is an adequate model for atypical PrPres formed in brain.
Indeed, inoculation of in vitro-generated F0.5-induced
atypical PrPres led to the de novo formation of atypical
PrPres in animals. Moreover, both F0.5-induced atypical
PrPres and brain-derived atypical PrPres gave rise to
PrPSc upon serial transmission. In both atypical PrPres
states, F0.5-induced and brain-derived, monoglycosylated
PrP was the predominant glycoform and hypersialylated
diglycosylated isoforms were missing. This is in contrast
to the glycosylation pattern of all currently known
Fig. 6 Plaques, perineuronal, perivascular or diffuse PrP depositions. PrP immunoreactivity stained with 3F4 antibody in subependymal (a), subpial
(b), cerebellum white matter (c), or deeper layer of cortex (d) in animals from the second passage of F0.5-induced atypical PrPres that developed clinical
disease. Red arrows point at perivascular deposition in c or perineuronal deposition in d. Scale bars = 50 μm
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hamster strains of synthetic or natural origin, in which
diglycosylated PrP is the predominant glycoform [37]. In
support of previous studies, this work argues that atyp-
ical PrPres can be faithfully and selectively propagated in
the dgPMCAb [26].
The mechanism in Fig. 1 postulates that evolution of
synthetic prions involves two main steps. Completing the
first step, which involved a transition from rPrP fibrils to
atypical PrPres, in vitro instead of in vivo did not
accelerate the disease development. This result suggests
that the major barrier on a pathway toward PrPSc is asso-
ciated with the second step, i.e. generation of PrPSc via de-
formed templating events, which are believed to be rare
and stochastic. The data on the dynamics between the
two forms suggest that atypical PrPres and PrPSc compete
with each other (Figs. 3 and 7). Atypical PrPres gives rise
to PrPSc in stochastic events that might occur earlier or
later in the course of infection. In experiments where the
first PrPSc arises from atypical PrPres before a critical
amount of atypical PrPres is accumulated, PrPSc is able to
propagate efficiently and rapidly replaces atypical PrPres
(Fig. 3d). If PrPSc appears later in the course of the infec-
tion when the amount of atypical is above a certain
threshold, PrPSc replication is slowed down. Inoculation of
atypical PrPres material, which was selectively amplified in
dgPMCA and free of PrPSc, proved its ability to produce
PrPSc in animals. However, it also provided a selective ad-
vantage to the propagation of atypical PrPres conforma-
tions. Under such inoculation conditions, PrPSc
accumulation during the first passage was very weak. Sev-
eral passages might be needed for the PrPSc to rich a level,
at which it exceed and effectively outcompete atypical
PrPres as it was observed with S05 [11]. With the atypical
PrPres inhibiting propagation of the disease-related forms
we have an interesting case of a “protective misfolding”,
where PrPC recruitment into an alternative misfolded, PK-
resistant, non-toxic, self-replicating state delays develop-
ment of a deadly disease.
Atypical PrPres is remarkable with respect to its bio-
chemical and biological properties. While fully transmis-
sible in animal studies, this is a clinically silent state, which
in the absence of PrPSc does not cause prion diseases or
clinical symptoms [11, 12, 25]. Atypical PrPres forms large
plaques and diffuse synaptic oligomers, however, neither is
associated with neurotoxic or pathogenic effects [25].
Atypical PrPres is structurally different from PrPSc, as
evident from the differences in length of PK-resistant frag-
ments, glycoform ratios and RNA-dependency of their
amplification in vitro [11, 12, 26, 27]. Moreover, the current
study established that atypical PrPres and PrPSc exhibit sig-
nificantly different sialylation patterns. In accordance with
previous work [35], PrPSc was found to contain PrP mole-
cules with a wide range of sialylation levels encompassing
molecules with both highly and moderately sialylated gly-
cans. In contrast to PrPSc, atypical PrPres does not recruit
PrPC with high levels of sialylation. Negatively charged
sialic acid residues create electrostatic repulsion between
neighboring N-linked glycans. Differences in sialylation
status suggest that atypical PrPres has much stronger
structural constraints for recruiting diglycosylated or heav-
ily sialylated molecules than PrPSc. As a result, only a frac-
tion of PrPC that is acceptable as a substrate for PrPSc is
also acceptable to atypical PrPres. Differences in sialylation
Fig. 7 Dynamics between atypical PrPres and PrPSc in animals from
the first and second passages. a Western blots of brain materials from
animals of the first and second passages of F0.5-induced atypical PrPres.
Brain material from an animal of the second passage of F0.5 (S05)
included as a reference. b Western blots of brain materials from
animals of the first, second and third passages of F0.5 fibrils. Arrows
indicate animals that were used for preparing inoculums for the
subsequent passages. Western blots were stained with SAF-84 or 3F4
antibody as indicated. c Brain materials from 263K- or S05-inoculated
animals or second passage of F0.5 fibrils were treated with PNGase and
PK, analyzed by Western blot and stained with 3F4
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offer one of the possible explanations why atypical PrPres
replicates slower than PrPSc and why PrPSc can eventually
outcompete atypical PrPres. Differences in sialylation
pattern could also be responsible for the lack of toxicity by
atypical PrPres. This hypothesis remains to be tested.
Alternatively, the lack of neurotoxicity could be due to the
absence of structural determinants associated with toxic
effects. Another hypothesis that would be interesting to
consider in future studies is whether sialylation deficiency
observed in certain genetic or metabolic disorders can
facilitate conversion of PrPC into alternative self-replicating
states similar to atypical PrPres or CTF12/13 associated
with sCJD.
A number of atypical or short PK-resistant fragments
has been identified in human and animal prion dis-
eases. PK-resistant fragments referred to as CTF12/13
that encompass residues 154/156-231 and 162/167-231
were found in the majority of patients with sCJD [38].
C-terminal PK-resistant species of similar size were
also found in iatrogenic CJD [39] and in mice infected
with mouse-passaged hamster scrapie [40]. Further-
more, similar C-terminal PK-resistant fragments were
found in atypical bovine spongiform encephalopathy,
which is believed to be sporadic in origin [41], and in
certain types of ovine scrapie [42]. While the size and
position of PK-resistant fragments of atypical PrPres
described in the current study are very similar to those
found in human and animal diseases of natural origin,
it is not clear whether they are structurally related or
play similar role in disease etiology. Moreover, the rela-
tionship of the C-terminal fragments found in sCJD,
iatrogenic CJD or in atypical bovine spongiform
encephalopathy to PrPSc is also uncertain. Taking into
account results presented here, one can speculate that
CTF12/13 species are precursors of PrPSc and import-
ant for the etiology of sporadic CJD. Testing this
hypothesis would involve selective amplification of
sCJD-derived CTF12/13 species in dgPMCAb to gener-
ate CTF12/13 material free of PrPSc and then testing
whether this material induce prion diseases with sCJD
phenotype in humanized mice. Comparison of the
sialylation status of atypical PK resistant fragments in
prion diseases of natural and synthetic origin would
help to establish a relationship between them as well as
their relationship with PrPSc.
This work highlights the role of deformed templating in
transformation and evolution of protein self-replicating
states. The deformed templating model predicts emergence
of new, structurally altered self-replicating states upon
changes in replication environment [16]. In agreement
with this prediction, treatments with anti-prion drugs or
prion inhibitors were found to result in transformation of
strain-specific properties and emergence of drug-resistant
prions [20, 43–45].
Conclusions
In summary, the current work illustrate for the first
time that transmissible prion disease with similar dis-
ease phenotype can be produced via two alternative
procedures: direct inoculation of recombinant PrP
amyloid fibrils or in vitro-produced atypical PrPres.
Moreover, this work showed that preparations of atyp-
ical PrPres free of PrPSc can give rise to transmissible
diseases in wild type animals and that atypical PrPres
generated in vitro is an adequate model for brain-
derived atypical PrPres. Finally, the current study
illustrates a remarkable case of competition between
two transmissible states formed by the same protein,
where one state being clinically silent, whereas another
being neurotoxic and responsible for progression of
disease. Differences in sialylation patterns between
PrPSc and atypical PrPres revealed that only a fraction
of PrPC that is acceptable as a substrate for PrPSc is also
acceptable to atypical PrPres. This explains why atyp-
ical PrPres replicates slower than PrPSc and why PrPSc
can eventually outcompete atypical PrPres. Other amy-
loidogenic proteins that are responsible for a range of
neurodegenerative disease are known to spread via
prion-like mechanisms [46, 47]. It remains to be deter-
mined whether competition between clinically silent
and toxic states is a general phenomenon or specific to
the prion protein.
Additional files
Additional file 1: Figure S1. Establishing a limiting dilution of atypical
PrPres in S05 brain material. S05 brain material was serially diluted up to
1013-fold, then each dilution was used to seed serial dgPMCAb; 18 serial
dgPMCAb rounds were conducted and analyzed by Western blot. Ten
serial PMCAb rounds were sufficient to amplify the highest dilution of
brain material that still contains atypical PrPres (109-fold dilution) to the
level detectible by Western blot. The reactions seeded with 1010-fold or
higher dilutions were all negative regardless of the number of serial
dgPMCAb rounds (Fig. 2c). Western blots were stained with SAF-84
antibody. (TIF 1376 kb)
Additional file 2: Figure S2. PK-resistance and conformational stability
of atypical PrPres and PrPSc. a Analysis of PK-resistance. Brain material from
S05-inoculated animals that contained predominantly PrPSc (upper panel) or
atypical PrPres (lower panel) were treated with increasing concentration of
glycerol-free proteinase and analyzed by Western blot. b Analysis of
conformational stability. Brain materials from S05-inoculated animals
that contained predominantly PrPSc (upper panel) or atypical PrPres (lower
panel) were incubated with increasing concentrations of GdnHCl, digested
with PK and analyzed by Western blot. Animals from the second passage of
S05 were used. Western blots were stained with 3F4 or SAF-84 antibody as
indicated. (TIF 1302 kb)
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